✦ LIBER ✦

Mistletoe Extract Reduces the Surgical Suppression of Natural Killer Cell Activity in Cancer Patients. A Randomized Phase III Trial

✍ Scribed by Schink, Michael ;Tröger, Wilfried ;Dabidian, Ali ;Goyert, Andreas ;Scheuerecker, Heinz ;Meyer, Johannes ;Fischer, Imma U. ;Glaser, Florian

Book ID: 120180779
Publisher: S. Karger AG
Year: 2007
Tongue: English
Weight: 151 KB
Volume: 14
Category: Article
ISSN: 2504-2092
DOI: 10.1159/000098135

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase iii randomized trial of interleuki

Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma

✍ Teresa Murray Law; Robert J. Motzer; Madhu Mazumdar; Kenneth W. Sell; Philip Wal 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 723 KB

Background. Treatment with interleukin-2 (IL-2) and lymphokine-activated killer cells (LAK) resulted in responses in some patients with advanced renal cell carcinoma (RCC). However, the relative therapeutic benefit of the addition of LAK to IL-2 was unknown. Methods. A randomized Phase I11 trial wa

The effect of surgery on natural killer

The effect of surgery on natural killer cell activity in head and neck cancer patients: In vitro reversal of a postoperatively suppressed immunosurveillance system

✍ Stimson P. Schantz; Marvin M. Romsdahl; George F. Babcock; Kenji Nishioka; Helmu 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 633 KB

An open-label, randomized trial of the e

An open-label, randomized trial of the effects of macrophage versus granulocyte colony-stimulating factor on natural killer cell activity, lymphokine activated killer cell activity, interleukin-2 production, and leukocyte count in patients after chemotherapy for ovarian cancer

✍ Mitsuaki Suzuki; Michitaka Ohwada; Yoshio Shimizu; Muneo Yamada; Ikuo Sato 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 381 KB

6 A phase III randomized trial evaluatin

6 A phase III randomized trial evaluating in patients with advamced non small cell lung cancer (NSCLC) the addition of ifosfamide to a combination of cisplatin and carboplatin

✍ Sculier, J.P.; Paesmans, M.; Thiriaux, J.; Bureau, G.; Giner, V.; Efremidis, A.; 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 152 KB

Vinorelbine (VNR) plus best supportive c

Vinorelbine (VNR) plus best supportive care (BSC) vs. BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (PTS). Results of a phase III randomized trial

✍ Gridelli, C; Ianniello, GP; Maiorino, L; Brancaccio, L; Cigolari, S; Bilancia, D 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 229 KB

Randomized phase III trial of gemcitabin

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study

✍ Morabito, Alessandro; Gebbia, Vittorio; Di Maio, Massimo; Cinieri, Saverio; Viga 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 930 KB